Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The two major classes of antidiabetic drugs, sulfonylureas and metformin, may differentially affect macrovascular complications and mortality in diabetic patients. We compared the long-term effects of glipizide and metformin on the major cardiovascular events in type 2 diabetic patients who had a history of coronary artery disease (CAD). RESEARCH DESIGN AND METHODS: This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. A total of 304 type 2 diabetic patients with CAD, mean age = 63.3 years (range, 36–80 years), were enrolled. Participants were randomly assigned to receive either glipizide (30 mg daily) or metformin (1.5 g daily) for 3 years. The primary end points were times to the composite of recurrent cardiovascular events, including death from a cardiovascular cause, death from any cause, nonfatal myocardial infarction, nonfatal stroke, or arterial revascularization. RESULTS: At the end of study drug administration, both groups achieved a significant decrease in the level of glycated hemoglobin (7.1% in the glipizide group and 7.0% in the metformin group). At a median follow-up of 5.0 years, 91 participants had developed 103 primary end points. Intention-to-treat analysis showed an adjusted hazard ratio (HR) of 0.54 (95% CI 0.30–0.90; P = 0.026) for the composites of cardiovascular events among the patients that received metformin, compared with glipizide. The secondary end points and adverse events were not significantly different between the two groups. CONCLUSIONS: Treatment with metformin for 3 years substantially reduced major cardiovascular events in a median follow-up of 5.0 years compared with glipizide. Our results indicated a potential benefit of metformin therapy on cardiovascular outcomes in high-risk patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Follow-up studies involving metformin appeared to support a potential cardiovascular benefit, but these studies were small and the findings were not robust.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [207]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Cited by
Items 201–300 of 366
Floyd, J. S., Wiggins, K. L., Christiansen, M. W., Dublin, S., Longstreth, W. T., Jr., Smith, N. L., McKnight, B., Heckbert, S. R., Weiss, N. S., & Psaty, B. M. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3914 · Cited by 11
“(%) 81 (20) 66 (27) 77 (17) Nephrotic syndrome, no.”
Long-term studies of treatments for type 2 diabetes
Caballero, A. E. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2017.1265417 · Cited by 12
“Long-term MET data report low hypoglycemia rates, both as monotherapy and in combination with insulin, with no associated weight gain [16,17] and glycemic control similar to SU at 3 years [16].”
BackgroundAli, A., Unnikannan, H., Shafarin, J., Bajbouj, K., Taneera, J., Muhammad, J. S., Hasan, H. A., Salehi, A. A., Awadallah, S. M., & Hamad, M. A. (2022) · Endocrine · doi:10.1007/s12020-022-03022-x · Cited by 12
“In the presence of PCSK9 however, LDLR/PCSK9 complexes fail to dissociate thus inhibiting LDLR recycling [1, 15, 27]; hence the increased risk of atherosclerosis and CVD that associate with increased PCSK9 synthesis [28–31].”
BackgroundGuo, H., Zhang, Q., Li, R., & Seshadri, V. D. (2022) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-022-04100-6 · Cited by 12
“During the exploration of effective anti-diabetic agents, the assessment of the efficiency of these agents to correct dyslipidemia is also considered an important step in order to develop them as a potential drug candidate [59, 60].”
BackgroundDifferential pharmacology and clinical utility of empagliflozin in type 2 diabetes
Davis, S. N., & Munir, K. M. (2016) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s77754 · Cited by 16
Therapy to Obese Type 2 Diabetes Mellitus: How Far Will We Go Down the Wrong Road?
Heng, X.-P., Li, X., Li, L., Yang, L., Wang, Z.-T., & Huang, S.-P. (2018) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-018-3053-8 · Cited by 11
Latest Evidence on Sulfonylureas: What’s New?
Leiter, L. A. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00812-2 · Cited by 12
Nrf2 Signaling Pathway as a Key to Treatment for Diabetic Dyslipidemia and Atherosclerosis
Yi, M., Toribio, A. J., Salem, Y., Alexander, M., Ferrey, A., Swentek, L., Tantisattamo, E., & Ichii, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115831 · Cited by 11
“Besides its anti-atherosclerotic feature, acacetin also exerts its antidiabetic effects by alleviating insulin resistance via regulation of Treg/T helper 17 (Th17) balance [106] and enhancing glucose uptake via the promotion of glucose transporter type 4 (GLUT4) translocation [107].”
BackgroundA review on cardiovascular effects of newer hypoglycaemic medications
Cutshall, B. T., Twilla, J. D., Olinger, A. S., & Oliphant, C. S. (2017) · Annals of Medicine · doi:10.1080/07853890.2017.1335428 · Cited by 10
“More recently, a randomized, double-blind trial comparing glipizide to metformin in 304 Chinese patients with T2DM and coronary artery disease (CAD) found increased rates of CV events and all-cause mortality with glyburide [15].”
BackgroundMałodobra-Mazur, M., Lewoń, D., Cierzniak, A., Okulus, M., & Gliszczyńska, A. (2021) · Nutrients · doi:10.3390/nu13103619 · Cited by 10
“Except for the pharmacological agents, various natural compounds derived from plant extracts, spices, herbs, and essential oils have been demonstrated to provide health benefits concerning insulin sensitivity, while being distributed in combination with pharmacotherapy or as the replacement therapy in the early stages…”
BackgroundHussan, K. P. S., A, A. R. K., Medammal, Z., Thayyil, M. S., & Babu, T. D. (2022) · Free Radical Research · doi:10.1080/10715762.2022.2034803 · Cited by 10
Novel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease
Oikonomou, E. K., Xenou, M., Zakynthinos, G. Ε., Tsaplaris, P., Lampsas, S., Bletsa, E., Gialamas, I., Kalogeras, K. I., Goliopoulou, A., Gounaridi, M. I., et al. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230703161058 · Cited by 12
The cardiovascular effects of metformin: lost in translation?
Riksen, N. P., & Tack, C. J. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000128 · Cited by 11
Lee, K., Lee, J. S., & Jung, K. (2018) · BMC Neurology · doi:10.1186/s12883-018-1109-1 · Cited by 12
Shivaswamy, V., Kedia, R., Kulkarni, S., & Ross, M. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s85748 · Cited by 10
Hong, J., Zhang, Y., Lai, S., & Ning, G. (2013) · Diabetes Care · doi:10.2337/dc13-2003 · Cited by 10
“Contrary to what Lund and Gong described, we state in the randomization and study medication section of the article that the study participants were randomly assigned to receive medications for 3 years.”
BackgroundInfluentialSelf-citationMazón‐Ramos, P., Cordero, A., González‐Juanatey, J. R., Martínez, V. B., Delgado, E., Vitale, G. C., & Fernández-Anaya, S. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2014.03.021 · Cited by 11
Guidelines on primary healthcare for type 2 diabetes in China, 2025
Jia, W., Zhu, D., Guo, L., Chen, L., Cai, C., & Song, J. (2025) · Family Medicine and Community Health · doi:10.1136/fmch-2025-003765 · Cited by 11
“14 The major adverse effects are gastrointestinal reactions, and serious adverse reactions include lactic acidosis.”
Self-citationMetformin Inhibits the Expression of Biomarkers of Fibrosis of EPCs In Vitro
Han, F., Shu, J., Wang, S., Tang, C., & Luo, F. (2019) · Stem Cells International · doi:10.1155/2019/9019648 · Cited by 9
Toma, T., Miyakawa, N., Arakaki, Y., Watanabe, T., Nakahara, R., Ali, T. F. S., Biswas, T., Todaka, M., Kondo, T., Fujita, M., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06260-y · Cited by 10
“Metformin has long been used as a first-line therapy for type 2 diabetes; it has anticancer, cardioprotective, neuroprotective, moderate hypoglycaemic and weight-loss-inducing effects [17–19].”
Metformin regulates myoblast differentiation through an AMPK-dependent mechanism
Maniscalco, E., Abbadessa, G., Giordano, M., Grasso, L., Borrione, P., & Racca, S. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281718 · Cited by 11
Qiu, X., Zheng, S., Wang, Y., Wang, R., & Ye, L. (2014) · Journal of Chromatographic Science · doi:10.1093/chromsci/bmu023 · Cited by 9
Ke, C., Morgan, S., Smolina, K., Gašević, D., Qian, H., & Khan, N. A. (2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.08.218 · Cited by 9
Understanding the cardiovascular risk with non-insulin antidiabetic drugs
Athyros, V. G., Imprialos, K. P., Stavropoulos, K., Sahinidis, A., & Doumas, M. N. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1586881 · Cited by 10
Paredes, S., Matta-Coelho, C., Monteiro, A. M., Brás, A., Marques, O., Alves, M., & Ribeiro, L. V. P. T. (2016) · HORMONES · doi:10.14310/horm.2002.1671 · Cited by 10
Yu, Z., Wang, J., Luo, W., Tse, R. T., & Pau, G. (2024) · Knowledge and Information Systems · doi:10.1007/s10115-024-02188-2 · Cited by 9
“This implies that the occurrence of side effects (i.e., the potential for adverse health outcomes) associated with pharmaceuticals tends to manifest following repeated administration, which is consistent with common sense in drug use [55, 56].”
Metformin Protects Cardiovascular Health in People With Diabetes
Chen, C., Yuan, S., Zhao, X., Qiao, M., Li, S., He, N., Huang, L., & Lyu, J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.949113 · Cited by 9
Kanaoka, K., Iwanaga, Y., Nakai, M., Nishioka, Y., Myojin, T., Kubo, S., Okada, K., Noda, T., Sakata, Y., Miyamoto, Y., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad035 · Cited by 8
Flory, J., Ukena, J., & Floyd, J. S. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0633-y · Cited by 9
Usmani, N., Ghosh, S., Sanghera, K. P., Ong, A. D., Koul, R., Dubey, A., Ahmed, S., Quon, H. C., Yee, D., Parliament, M. B., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.07.035 · Cited by 9
SAKOUHI, M., Matmour, D., Belakhdar, K., & Kraroubi, A. (2022) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2022.11.013 · Cited by 9
Management Protocols of stable coronary artery disease in India: Executive summary
Mishra, S., Ray, S., Dalal, J. J., Sawhney, J. P. S., Ramakrishnan, S., Nair, T., Iyengar, S., & Bahl, V. K. (2016) · Indian Heart Journal · doi:10.1016/j.ihj.2016.11.318 · Cited by 9
Use of Metformin and Platelet Reactivity in Diabetic Patients Treated with Dual Antiplatelet Therapy
Verdoia, M., Pergolini, P., Rolla, R., Ceccon, C., Caputo, M., Aimaretti, G., Suryapranata, H., & Luca, G. D. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0787-1382 · Cited by 9
Khinchin, J., Rakoubian, A., Romano, V. C., Ryan, T., Yarbro, J. R., Kobayashi, S., & Liang, Q. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1681783 · Cited by 13
“…is consistently associated with a lower incidence of cardiovascular events compared with sulfonylureas or insulin, even with similar glycemic control (Hong et al., 2013), although one study reported reductions primarily in all-cause rather than cardiovascular mortality (Bergmark et al., 2019).”
Zhang, Y., Li, Z., & Hao, Y. (2025) · European journal of medical research · doi:10.1186/s40001-024-02241-4 · Cited by 13
“A study conducted in China showed a significant reduction in the recurrence of major cardiovascular events after a median 5.0 years of follow-up with metformin treatment compared to glipizide [14].”
InfluentialSelf-citationDose modification of antidiabetic agents in patients with type 2 diabetes mellitus and heart failure
Sharma, D., Asirvatham, A. J., & Singh, P. (2017) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_442_16 · Cited by 8
“[59,60] In contrast, another study found that metformin demonstrated its superiority over gliclazide in terms of CV safety.[61]”
ResultAbdel-Moneim, A.-M. H., Lutfi, M. F., Alsharidah, A. S., Shaker, G. A., Faisal, W., Abdellatif, A. A. H., Rugaie, O. A., Mohany, K. M., Eid, S. Y., El-Readi, M. Z., et al. (2022) · Applied Sciences · doi:10.3390/app12042019 · Cited by 10
“reduced major cardiovascular events compared to therapy with glipizide over a median follow-up time of 5 years [17].”
BackgroundIn Vitro and In Ovo Evaluation of the Potential Hepatoprotective Effect of Metformin
Cozma, G. V., Apostu, A., Macasoi, I. G., Dehelean, C. A., Cretu, O. M., Dinu, Ş., Gaiță, D. I., & Manea, A. M. (2022) · Medicina · doi:10.3390/medicina58060705 · Cited by 7
“Since Met has been used in therapy for over 50 years, alternative potential therapeutic activities are currently being investigated and intensively discussed, such as its antitumoral [5], antiaging action [6], or cardioprotective action [7].”
Noguchi, Y., Yoshizawa, S., Tachi, T., & Teramachi, H. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11174988 · Cited by 8
An ADAM17 selective inhibitor promotes glucose uptake by activating AMPK
Toma, T., Miyakawa, N., Tateishi, M., Todaka, M., Kondo, T., Fujita, M., Otsuka, M., Araki, E., & Tateishi, H. (2023) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2023.11.005 · Cited by 8
Rados, D. R. V., Viecceli, C., Pinto, L. C. F., Gerchman, F., Leitão, C. B., & Gross, J. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-69738-w · Cited by 7
Top, W. M. C., Lehert, P., Schalkwijk, C. G., Stehouwer, C. D. A., & Kooy, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247939 · Cited by 9
“A third trial, the SPREAD DIMCAD trial showed a 46% reduction in recurrent cardiovascular events by metformin when compared to the active comparator glipizide [15].”
BackgroundWu, Y., Tang, L., Zhang, F., Yan, Z., Li, J., & Tong, N. (2018) · International Journal of Endocrinology · doi:10.1155/2018/8457538 · Cited by 9
Raghavan, S., Liu, W. G., Saxon, D. R., Grunwald, G. K., Maddox, T. M., Reusch, J. E. B., Berkowitz, S. A., & Caplan, L. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000516 · Cited by 9
“14 24 Our results support the findings of a small randomized trial that found improved 5-year mortality outcomes associated with metformin treatment compared with sulfonylurea treatment in individuals with diabetes and CAD.(24) On the other hand, our results contrast with those of a study of individuals with diabetes…”
ResultInfluentialMetformin suppresses atherosclerosis by dampening extramedullary myelopoiesis
Lee, M. K., Cooney, O. D., Zhu, Y., Zhang, Y., Lin, X., Onda, D.-A., Galić, S., Kemp, B. E., Murphy, A. J., & Loh, K. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00056.2025 · Cited by 7
Self-citationEffects of glucose-lowering agents on ischemic stroke
Avgerinos, K. I., & Τζιόμαλος, Κ. (2017) · World Journal of Diabetes · doi:10.4239/wjd.v8.i6.270 · Cited by 8
Nishimura, R., Takeshima, T., Iwasaki, K., & Aoi, S. (2022) · BMJ Open · doi:10.1136/bmjopen-2020-045966 · Cited by 6
Selective somatostatin receptor 5 inhibition improves hepatic insulin sensitivity
Tamura, Y. O., Sugama, J., Abe, S., Shimizu, Y., Hirose, H., & Watanabe, M. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1043 · Cited by 5
Group sequential designs with robust semiparametric recurrent event models
Mütze, T., Glimm, E., Schmidli, H., & Friede, T. (2018) · Statistical Methods in Medical Research · doi:10.1177/0962280218780538 · Cited by 7
Ciresi, A., Vigneri, E., Radellini, S., Pantò, F., & Giordano, C. S. D. S. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0338-4 · Cited by 7
Modulation of Cardiomyocyte and Hepatocyte Bioenergetics by Biguanides
Almarzooqi, S. S. (2014) · Journal of Clinical Toxicology · doi:10.4172/2161-0495.1000203 · Cited by 6
“metformin on enhancing cardiac function and decreasing risk of diabetes associated cardiomyopathy [32,33].”
BackgroundA Calibration Approach to Transportability with Observational DataPreprint
Josey, K., Yang, F., Ghosh, D., & Raghavan, S. (2020) · arXiv (Cornell University) · Cited by 6
Wong, H. J., Lin, N., Teo, Y. N., Syn, N. L. X., Teo, Y. H., & Sia, C. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00640-w · Cited by 7
Management Guidelines for Diabetic Patients With Hypertension
Wang, W., Wan, Q., Wang, S., Ning, G., Bi, Y., Liu, L., Liu, Y., Liu, Y., Li, X., Li, T., et al. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70093 · Cited by 11
Self-citationNarcisse, D. I., Katzenberger, D. R., & Gutierrez, J. A. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01677-6 · Cited by 4
Somsuan, K., Aluksanasuwan, S., Woottisin, S., Chiangjong, W., Wanta, A., Munkong, N., Jaidee, W., Praman, S., Fuangfoo, K., Morchang, A., et al. (2024) · Journal of Molecular Histology · doi:10.1007/s10735-024-10258-6 · Cited by 6
“Abnormal metabolic signals from adipose tissue, including adipokines and excess lipids, contribute to insulin resistance, which is linked to conditions such as obesity, T2DM, metabolic dysfunction-associated fatty liver disease (MAFLD), and cardiovascular disease.”
InfluentialThe ‘Old' Anti-Diabetic Agents: A Systematic Inventory
Buhse, S., Mühlhauser, I., & Lenz, M. (2016) · Endocrine development · doi:10.1159/000439369 · Cited by 6
Interpreting Cardiovascular Endpoints in Trials of Antihyperglycemic Drugs
Chawla, H., & Tandon, N. (2017) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-017-0215-6 · Cited by 5
“Patients continued to receive standard of care therapy for T2DM and CVD and were randomized to placebo or alogliptin 25 mg/day in patients with an eGFR of C60 mL/min/1.73 m2, 12.5 mg/day in those with an eGFR of 30 to \60 mL/min/1.73 m2, and 6.25 mg/day in those with an eGFR of\30 mL/min/1.73 m2.”
BackgroundInfluentialShould metformin be used in every patient with type 2 diabetes?
Makin, V., & Lansang, M. C. (2019) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.86a.18039 · Cited by 5
Κender, Ζ., Groener, J. B., Reismann, P., & Kopf, S. (2019) · Orvosi Hetilap · doi:10.1556/650.2019.31547 · Cited by 7
“Egyes tanulmányok azonban a metformin pozitív hatását igazolták a szív- és érrendszeri megbetegedésekre [36, 37], illetve ezek kockázati paramétereire (például szisztolés vérnyomás, arteria carotis intima-media vastagság) [16, 23, 38–40].”
McRae, M., & Wang, C. C. L. (2022) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2021.11.012 · Cited by 8
Management of Diabetes Mellitus
Jenkins, A. J., SCOTT, E. S., Fulcher, J., Kilov, G., & Januszewski, A. S. (2018) · Contemporary cardiology · doi:10.1007/978-3-319-97622-8_7 · Cited by 6
Sulfonylureas and meglitinides: insights into physiology and translational clinical utility
Lebovitz, H. E., & Melander, A. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch42 · Cited by 6
Lund, S. S., & Gong, Y. (2013) · Diabetes Care · doi:10.2337/dc13-1806 · Cited by 5
“Somewhat confusing, some of the 3-year data were reported as “end of follow-up,” while, except CV outcomes, corresponding data at the actual end of follow-up (5 years) were apparently not collected (1).”
BackgroundInfluentialGlucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms
BAJAJ, H. S., & Zinman, B. (2018) · Physiology · doi:10.1152/physiol.00004.2018 · Cited by 7
“” Two small randomized control trials, including the secondary analysis of UKPDS overweight patients, suggest cardiovascular benefit of metformin compared with sulfonylureas or insulin (61, 103).”
BackgroundGao, Q., Li, L., Bai, J., Fan, L., Tan, J., Wu, S., & Cai, J. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002669 · Cited by 5
“…(eg, metformin) have a protective effect on the cardiovascular system and could offset some of the potentially harmful effects of elevated BP. [25] In our sensitivity analysis, the exclusion of antihypertensive drugs, hypo-glycemic agents, or lipid-lowering drugs, generated similar results to…”
ResultEffect of Glipizide on non-insulin-dependent diabetes mellitus
Yuan, J. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v54i.9760 · Cited by 4
Estrada, A. K., Delgado‐Maldonado, T., Lara-Ramirez, E. E., Martínez-Vázquez, A. V., Ortíz-Pérez, E., Paz-González, A. D., Bandyopadhyay, D., & Rivera, G. (2021) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557521666210805112416 · Cited by 4
Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease
Yagyu, H., & Shimano, H. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13859 · Cited by 4
For debate; pharmacological priorities in advanced type 2 diabetes
Hodish, I. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107510 · Cited by 4
Role of Glucose and Lipids in the Atherosclerotic Cardiovascular Disease of Patients with Diabetes
Feingold, K. R. (2020) · Europe PMC (PubMed Central) · Cited by 5
The shifting paradigm in the treatment of type 2 diabetes mellitus—A cardiologist's perspective
Fatima, S., Jameel, A., Ayesha, F., & Menzies, D. J. (2017) · Clinical Cardiology · doi:10.1002/clc.22781 · Cited by 4
Encyclopaedic Review of Glipizide Pre-clinical and Clinical Status
Mohammed, S., Mahmood, T., Shamim, A., Ahsan, F., Shariq, M., Parveen, S., Waseem, R., & Singh, A. (2024) · Drug Research · doi:10.1055/a-2237-8566 · Cited by 3
Standard and Novel Treatment Options for Metabolic Syndrome and Diabetes Mellitus
Groves, E. M., Yu, K. M., Wong, N. D., & Malik, S. (2013) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-013-0273-2 · Cited by 3
Metformin in advanced chronic kidney disease: are current guidelines overly restrictive?
Cole, N. I., Swift, P. A., Suckling, R., & Andrews, P. (2016) · British Journal of Diabetes · doi:10.15277/bjd.2016.106 · Cited by 3
Will Cardiovascular Outcomes Data on Newer Diabetes Drugs Bury the Older Agents?
Flory, J. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.8284 · Cited by 3
Goyat, R., Rai, P., Chang, J., Ponte, C. D., & Tan, X. (2018) · Clinical Drug Investigation · doi:10.1007/s40261-018-0639-z · Cited by 3
“Blinding of outcome assessment was also poorly reported; two studies were at low risk [34, 38], three studies at high risk [35, 36, 39], and the remaining five studies at unclear risk [20, 31–33, 37].”
InfluentialDethroning the king?: The future of metformin as first line therapy in type 2 diabetes
Inzucchi, S. E., & Fonseca, V. A. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.03.003 · Cited by 4
Metformin, Microbiota and Health
Paz, G. S., & Fernandes, J. (2022) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2022.00032 · Cited by 3
Somasundaram, M., Mathew, S. K., Paul, S., Kurian, S. J., Kunhikatta, V., Karanth, S., Shetty, S., Kudru, C. U., Manu, M. K., Saravu, K., et al. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2425829 · Cited by 3
“…metformin’s ability to lower cardiovascular events in diabetes via enhanced expression of the angiotensin-converting enzyme 2 (ace2) receptor [18–21]. ace2 receptor binding is a crucial step for virus entry, but treatment options that increase ace2 expression may attenuate cOViD-19…”
BackgroundAntihyperglycemic Medications and Impact on Cardiovascular Outcomes: A Review of Current Evidence
Gale, S. E., Poon, J. L., & Watson, K. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2128 · Cited by 3
“The Study on the Prognosis and Effect of Antidiabetic Drugs on Type 2 Diabetes Mellitus with Coronary Artery Disease (SPREADDIMCAD) study addressed the CV benefits of metformin in patients with a CVD history.(7) Prior to this study, the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release C…”
MethodDiabetes and the Cardiovascular System
Rigato, M., Fadini, G. P., & Avogaro, A. (2019) · Endocrinology · doi:10.1007/978-3-319-27316-7_6-3 · Cited by 3
Top 20 research studies of 2013 for primary care physicians.
Ebell, M. H., & Grad, R. M. (2014) · PubMed · Cited by 3
Choxi, R., Roy, S., Stamatouli, A. M., Mayer, S., & Jovin, I. S. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1756778 · Cited by 3
Dubayee, M. A., Alshahrani, A. S., Aljada, D., Zhra, M., Alotaibi, A., Ababtain, I., Alnaim, M., Alahmari, A. M., Aljarallah, A., Elahi, M. A., et al. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s300048 · Cited by 4
and, J. T., & Boyle, J. (2022) · Wiley eBooks · doi:10.1002/9781119785033.ch2 · Cited by 3
Hamad, M. A., Muhammad, J. S., Rah, B., Hasan, H. A., Taneera, J., Soofi, A., & Awadallah, S. M. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300107 · Cited by 3
Vempati, R., Damarlapally, N., Roy, P., Mylavarapu, M., Vasudevan, S. S., Reguram, R., Vora, T., Jain, H., Ahmed, R., & Krishnamoorthy, G. (2025) · Diagnostics · doi:10.3390/diagnostics15182288 · Cited by 2
Diabetes Management and Cardiovascular Risk: Are SGLT-2 Inhibitors the Safest?
Swislocki, A., & Jialal, I. (2015) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2015.29003.swi · Cited by 2
Elnaem, M. H., Azam, F. M., & Akkawi, M. E. (2020) · IIUM Medical Journal Malaysia · doi:10.31436/imjm.v19i3.1671 · Cited by 2
“agent, particularly in diabetic patients with coronary artery diseases.(32) As a combination therapy, S.”
BackgroundUrsavaş, S., Kuyucu, Y., Yenilmez, E. D., Tuli, A., Tekayev, M., & Mete, U. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151507 · Cited by 2
Metformin: Its salutary effects beyond diabetes mellitus
Sawalha, K., Gautam, N., Sivakumar, K., Paydak, H., & Mehta, J. L. (2025) · Journal of Investigative Medicine · doi:10.1177/10815589251327511 · Cited by 4
Scheen, A. J. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.04.014 · Cited by 2
Changing Fields-Diabetes Medications Invading the Cardiovascular Space
Breite, L. D., Steck, M., Cutshall, B. T., Shah, S. P., & Cave, B. E. (2020) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2020.100736 · Cited by 3
Mazón‐Ramos, P., Cordero, A., González‐Juanatey, J. R., Bertoméu, V., Delgado, E., Vitale, G. C., & Fernández-Anaya, S. (2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2014.03.021 · Cited by 3
Zhang, F., Tang, L., Li, J., Yan, Z., Li, J., & Tong, N. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s293307 · Cited by 4
“For example, the PROactive study found that pioglitazone may significantly reduce the risk of microvascular complications and cardiovascular disease (CVD) in patients with T2D.11 The IRIS study demonstrated that pioglitazone may significantly reduce the risk of both stroke recurrence and myocardial infarction in non-d…”
ResultInfluentialMetformin, Sulfonylureas, DPP-4 Inhibitors and Cardiovascular Outcomes in Type 2 DM
Scheen, A. J. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_32 · Cited by 2
Kp, Z., & Furmanova, O. V. (2018) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.14.2.2018.130564 · Cited by 3
Role of Endoplasmic Reticulum ER Stress-Induced Cell Death Mechanisms
Madkour, L. H. (2020) · Nanomedicine and nanotoxicology · doi:10.1007/978-3-030-37297-2_8 · Cited by 2
Andari, E., Arnaout, S., Azar, S. T., Chammas, E., Jambart, S., Saleh, M., Nemr, R., & Sarkis, A. (2020) · Current Diabetes Reviews · doi:10.2174/1573399816666200120122929 · Cited by 2
Metadata
- Authors
- Hong, J., Zhang, Y., Lai, S., Lv, A., Su, Q., Dong, Y., Zhou, Z., Tang, W., Zhao, J., Cui, L., Zou, D., Wang, D., Li, H., Liu, C., Wu, G., Shen, J., Zhu, D., Wang, W., Shen, W., Ning, G., & on behalf of the SPREAD-DIMCAD Investigators
- Affiliations
- Shanghai Jiao Tong University (CN)
- Johns Hopkins University (US)
- Second Xiangya Hospital of Central South University (CN)
- Shandong University (CN)
- Second Military Medical University (CN)
- The First Affiliated Hospital of Wenzhou Medical College, Zhejiang Province, China
- Sir Run Run Shaw Hospital (CN)
- Jiangsu Province Hospital (CN)
- Shanghai Ten’s People’s Hospital of Tongji University, Shanghai, China
- Nanfang Hospital (CN)
- Nanjing Drum Tower Hospital (CN)
- Corresponding author
- Ning, Guang
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-04-13
- Volume
- 36
- Issue
- 5
- Pages
- 1304-1311
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3631843
- OpenAlex
- W2141199290
- Cited by
- 366
- References
- 37
- Citations by year
- 2026: 7 · 2025: 16 · 2024: 20 · 2023: 26 · 2022: 43 · 2021: 35 · 2020: 44 · 2019: 31 · 2018: 31 · 2017: 28 · 2016: 30 · 2015: 20 · 2014: 22 · 2013: 12
- FWCI
- 14.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81170784, 1994DP131044, 201002002, 2012ZX09303006-001, 30971077)
- Shanghai Municipal Education Commission
- National Key New Drug Creation and Manufacturing Program, Ministry of Science and Technology (2012ZX09303006‐001)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- metformin, glipizide, type 2 diabetes, coronary artery disease, cardiovascular outcomes, sulfonylureas, myocardial infarction, stroke, cardiovascular mortality, HbA1c, macrovascular complications
- MeSH terms
- Adult, Aged, Aged, 80 and over, Coronary Artery Disease, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glipizide, Humans, Male, Metformin, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.